St. John's Wort---An Herbal Myth or a Botanical Miracle
Herbal products such as St. John's Wort are a multi-billion dollar industry word-wide. St. John's Wort has been widely used for treatment of several biological ailments, including depression. This paper focuses solely on the relationship between medicinal properties of St. John's Wort and its effectiveness as a treatment for depression. There have been many studies in US and Europe aimed at establishing the effectiveness of St. John's Wort as a natural remedy for depression. The results of these studies are mixed. While some individuals may experience relief from depression by taking St. John' Wort many do not.
Psychotropic Drugs, Herbal Medicine, Medicinal Chemistry
[1]
De Smet PA. Herbal remedies. New England Journal of Medicine. 2002;347(25):2046-2056.
[2]
Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St. John's wort) in major depressive disorder: a randomized controlled trial. Journal of the American Medical Association. 2002;287(14):1807-1814.
[3]
National Center for Complementary and Alternative Medicine. St. John's Wort and Depression. National Center for Complementary and Alternative Medicine Web site. Accessed at nccam.nih.gov/health/stjohnswort/sjw-and-depression.htm on August 24, 2010.
[4]
St. John's wort. Natural Medicines Comprehensive Database Web site. Accessed at www.naturaldatabase.com on October 15, 2010.
[5]
St. John's wort. In: Blumenthal M, Goldberg A, Brinckman J, eds. Herbal Medicine: Expanded Commission E Monographs. Newton, MA: Lippincott Williams and Wilkins; 2000:359-366.
[6]
St. John's wort (Hypericum perforatum L.). Natural Standard Database Web site. Accessed at www.naturalstandard.com on October 15, 2010.
[7]
Bamber, B.A., Beg, A.A., Twyman, R.E., and Jorgensen, E.M. (1999). The Caenorhabditiselegans unc-49 locus encodes multiple subunits of a heteromultimeric GABA receptor. J. Neurosci. 19, 5348-5359
[8]
Bamber, B.A., Richmond, J.E., Otto, J.F., and Jorgensen, E.M. (2005). The composition of the GABA receptor at the Caenorhabditiselegans neuromuscular junction. Br. J. Pharmacol. 144, 502-509
[9]
Bamber, B.A., Twyman, R.E., and Jorgensen, E.M. (2003). Pharmacological characterization of the homomeric and heteromeric UNC-49 GABA receptors in C. elegans. Br. J. Pharmacol
[10]
Bazemore, A.W., Elliott, K.A. C., and Florey, E. (1957). Isolation of factor I. J. Neurochem. 1, 334-339.
[11]
Berger M, Gray JA, Roth BL (2009). "The expanded biology of serotonin". Annu. Rev. Med. 60: 355-66.
[12]
Kang K, Park S, Kim YS, Lee S, Back K (2009). "Biosynthesis and biotechnological production of serotonin derivatives". Appl. Microbiol. Biotechnol. 83 (1): 27-34
[13]
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003). "Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene". Science 301 (5631): 386-9.
[14]
Matondo RB, Punt C, Homberg J, Toussaint MJ, Kisjes R, Korporaal SJ, Akkerman JW, Cuppen E, de Bruin A (2009). "Deletion of the serotonin transporter in rats disturbs serotonin homeostasis without impairing liver regeneration". Am. J. Physiol. Gastrointest. Liver Physiol. 296 (4): G963-8
[15]
Wong ML, Khatri P, Licinio J, Esposito A, Gold PW. Identification of hypothalamic transcripts upregulated by antidepressants. BiochemBiophys Res Commun 1996;229:275-279.
[16]
Kessler RC, Walters EE. Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey. Depress Anxiety 1998;7:3-14.
[17]
American Psychiatric Association, DSM-IV. Diagnostic and statistical manual of mental disorders : DSM-IV. (4th ed.) Washington, DC: American Psychiatric Association, 1994.
[18]
Gold PW, Loriaux DL, Roy A, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med 1986;314:1329-1335.
[19]
Selye H. A syndrome produced by diverse nocious agents. Nature 1936;138:32.
[20]
Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress. N Engl J Med 1988;319:348-353 and 413-420.
[21]
Keith SJ, Matthews SM. The value of psychiatric treatment: its efficacy in severe mental disorders. Psychopharmacol Bull 1993;29:427-430.
[22]
Moller HJ, Volz HP. Drug treatment of depression in the 1990s. An overview of achievements and future possibilities. Drugs 1996;52:625-638.
[23]
Broekkamp CL, Leysen D, Peeters BW, Pinder RM. Prospects for improved antidepressants. J Med Chem 1995;38:4615-4633.
[24]
Muller WE, Kasper S. Clinically used antidepressant drugs. Pharmacopsychiatry 1997;2:71.
[25]
Erdelmeier CA. Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry 1998;1:2-6.
[26]
Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression--an overview and meta-analysis of randomised clinical trials. BMJ 1996;313:253-258.
[27]
Woelk H, Burkard G, Grunwald J. Benefits and risks of the Hypericum extract LI 160: drug monitoring study with 3250 patients. J Geriatr Psychiatry Neurol 1994:S34-38.
[28]
Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur J ClinPharmacol 1998;54:589-594.
[29]
Muller WE, Rolli M, Schafer C, Hafner U. Effects of Hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997;2:102-107.
[30]
Muller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiatry 1998;1:16-21.
[31]
Neary JT, Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res 1999;816:358-363.
[32]
Lieberman S. Nutriceutical review of St. John's wort (Hypericum perforatum) for the treatment of depression. J Womens Health 1998;7:177-182.
[33]
Kaehler ST, Sinner C, Chatterjee SS, Philippu A. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus. NeurosciLett 1999;262:199-202.
[34]
Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Muller WE. Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sci 1998;63:499-510.
[35]
Brady LS, Whitfield HJ, Fox RJ, Gold PW, Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 1991;87:831-837.
[36]
Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 1992;572:117-125.
[37]
Bhattacharya SK, Chakrabarti A, Chatterjee SS. Activity profiles of twohyperforin-containing Hypericum extracts in behavioral models. Pharmacopsychiat 1998; 31 (suppl): 22-29.
[38]
American Herbal Pharmacopoeia and Therapeutic Compendium. St. John's wort (Hypericum perforatum) Monograph. Herbalgram: The Journal of the American Botanical Council and the Herb Research Foundation. 1997;s (40):1-16.
[39]
Hypericum Depression Trial Study Group. "Effect of Hypericum perforatum (St. John's wort) in major depressive disorder: A Randomized, Controlled Trial". Journal of the American Medical Association. 2002; 287:1807-14.
[40]
Shelton RC, Keller MB, Gelenberg AJ, et al. Effectiveness of St. John's wort in major
[41]
depression. Journal of the American Medical Association. 2001; 285:1978-86.
[42]
Linde K, et al. St. John's wort for depression--An Overview and Meta-analysis of Randomized Clinical Trials. British Medical Journal. 1996; 313:253-8.
[43]
Piscitelli SC, et al. Indinavir concentrations and St. John's wort. The Lancet. 2000; 355:547-8.
[44]
Mathijssen RHJ, et al. Effects of St. John's wort on irinotecan metabolism. Journal of the
[45]
National Cancer Institute. 2002; 94:1247-9.
[46]
Fugh-Berman, A. Herb-drug interactions. Lancet 2000, 355(9198); 134-138.
[47]
Johne, A. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's Wort (Hypericum perforatum). Clin. Pharmacol. Ther. 1999; 66(4); 338- 45.
[48]
Ernst, E. Second thoughts about safety of St. John's Wort. Lancet 1999, 354(9195); 2014-2015.
[49]
Ruschitzka, R. et al. Acute heart transplant rejection due to Saint John's Wort. Lancet 2000;355(9203); 548- 549.
[50]
Yue, Q-Y, et al. Safety of St. John's Wort (Hypericum perforatum). Lancet 2000;355(9203); 576.
[51]
Nebel, A. et al. Potential metabolic interaction between St. John's Wort and theophylline. Ann. Pharmacother. 1999,33; 502.
[52]
Lantz, M.S. et al. St. John's Wort and antidepressant drug interactions in the elderly. J. Ger. Psych. Neur. 1999;12; 7-10.
[53]
Kasper S and Schulz V, St. Johns wort extract as plant antidepressant, SchweizRundsch Med Prax. 2000 Dec 21;89(51-52):2169-77
[54]
Poldinger W History of St. Johns wort SchweizRundsch Med Prax. 2000 Dec 14; 89(50):2102-9
[55]
Shelton RC, Keller MB, Gelenberg AJ, et al. Effectiveness of St. John's wort in major depression. Journal of the American Medical Association. 2001; 285:1978-86.
[56]
Muller WE et al, Mechanism of action of St. Johns wort extract SchweizRundsch Med Prax. 2000 Dec 14;89(50):2111-21
[57]
Fornasiero RB, Bianchi A, PinettiA (1998) Anatomical and ultrastructural observations in Hypericum perforatum L. leaves. J Herb Spices Med Plant 5: 21-33
[58]
Nahrstedt A, Butterwick V (1997) Biologically active and other chemical constituents of the herb of Hypericumperforatum L. Pharmacopsychiatry 30: 129-134
[59]
Upton R (1998) St. John's Wort: Quality Control, Analytical and Therapeutic Monograph. American Herbal Pharmacopoeia Compendium, Santa Cruz, CA
[60]
Zobayed, S. and Saxena, P.K. 2004. Production of St. John's Wort plants under controlled environment for maximizing biomass and secondary metabolites. In Vitro Cellular and Developmental Biology - Plant 40: 108-114.
[61]
Mosaleeyanon, K., Zobayed, S.M.A., Afreen, F. and Kozai, T. 2005. Relationships between net photosynthetic rate and secondary metabolite contents in St. John's wort. Plant Science 169: 523-531.
[62]
Intergovernmental Panel on Climate Change. Climate Change 2007: Synthesis Report. November 2007. Available at: http://www.ipcc.ch/ pdf/assessment-report/ar4/syr/ar4_syr.pdf.
[63]
Bruni R, Pellati F, Bellardi MG, Benvenuti S, Paltrinieri S, Bertaccini A et al. Herbal drug quality and phytochemical composition of Hypericum perforatum L. affected by ash yellows phytoplasma infection. J Agric Food Chem 2004;52:964-8.
